IPM Technology Transfer

Bids Invited for the transfer of Technologies

 

Sr. No.

Brief about Technology

Application Area and Related Industries

1.

A novel anti-cancer combination therapy

 

The present invention relates to the identification of new cellular target of micro-RNA- mir-24-2, i.e. BCL-2, an anti-apoptotic gene, and methods of its use to increase apoptosis (cell death) of cancer cells in presence of 200-400 fold reduced dose of anti-cancer drugs. The approach has the potential to reduce toxicity to non-cancerous cells considerably and allow improved quality of life during therapeutic intervention. The invention described here provides a new anti-cancer combination therapy that utilizes over-expression of mir-24-2 to potentiate the apoptotic pathway by down-regulating the expression of BCL-2, H2AFX, MDM2 and P21 genes. It has been demonstrated herein that treatment of breast cancer cells, MCF7, with anti-cancer drugs like, Cisplatin along with over-expression of micro-RNA, mir-24-2 has additive effect in inducing apoptotic cell death. A patent application for this IPR protection has been filed in 2011, displayed on Pg No 635 in "Official Journal of The Patent Office; Issue No 02/2013" (Click Here to Download)

 

Interested parties who want to bid for the technology may submit their bid in the office of chairperson, Intellectual Property Management Cell, Room No. 117, Administration Block, Jawaharlal Nehru University, New Delhi-110067, so as to reach this office on or before 30th November, 2014. For any further clarification and seeking appointment the interested parties can contact: Prof R N K Bamezai, School of Life Sciences, Jawaharlal Nehru University, New Delhi-110067 by email: bamezai@hotmail.com or phone +91 11 26704518.

 

Click Here to Download 

 

All Pharmaceutical Industries

2.

Nutritionally Improved Rice fortified with High Lysine

 

In the major cereal grains (wheat, rice, maize etc.), which represent the largest source of food and feed worldwide, lysine is the most limiting essential amino acid and it is therefore considered as a nutritionally significant amino acid. Rice is the most important staple food for a large part of world's population, especially in East and South Asia, the Middle East, Latin America, and the West Indies. Rice grains are deficient in certain essential amino acids, especially lysine. Lysine plays a major role in calcium absorption; building muscle protein; recovering from surgery or sport injuries; and production of hormones, enzymes and antibodies. It also helps to prevent herpes and osteoporosis. Lysine deficiency results in appetite loss, poor growth, fatigue, anemia etc. We need 51 milligrams of lysine, also called L-lysine, for each gram of protein we eat. Therefore, the average woman should get approximately 2.3 grams of lysine per day, and the average man should get about 2.8 grams. Lysine promotes proper organ development and muscle growth. It helps in production of carnitine, a nutrient responsible for converting fatty acids into energy and helping our body to lower the cholesterol. Therefore, efforts are being made to improve the nutritional quality of rice with high lysine content. In light of these implications, we have done metabolic engineering in rice to increase its lysine contents. It is also estimated that increasing lysine content could increase the gross value of rice in world feed market. A patent application for this IPR protection has been filed.

 

Interested parties who want to bid for the technology may submit their bid in the office of chairperson, Intellectual Property Management Cell, Room No. 117, Administration Block, Jawaharlal Nehru University, New Delhi-110067, so as to reach this office on or before 31st October, 2014. For any further clarification and seeking appointment the interested parties can contact: Professor Ashwani Pareek, School of Life Sciences, Jawaharlal Nehru University, New Delhi-110067 by email: ashwanipareek@gmail.com or phone +91 11 26704504.

 

Plant Biotechnology, Pharmaceutical and Seed Industries

3.

A non-GM based improved rice with higher yields capable of growing under high temperature, mild drought and poor quality water (salinity)

 

The present invention provides an improved and novel rice type which is having high yield and is also tolerant to multiple abiotic stresses (high temperature, drought and salinity or poor quality water). This novel rice type has the capacity to produce higher grains under control as well as under various abiotic stress conditions. This is a dwarf rice and hence, easy to handle during farming. This rice plant shows early maturity and short life span than the wild type (WT, cv IR64). Grain size of this rice with or without husk or after boiling is bigger than the WT. Grain weight of the developed rice is also higher than that of WT. This rice can be highly suitable for its further use in industries or in farming. A patent application for this IPR protection has been filed.

 

http://www.jnu.ac.in/IPM_Cell/technology_clip_image002.gif 

 

 

 

 

Figure: Phenotype of WT and investigated rice plants along with their panicle morphology.

 

Interested parties who want to bid for the technology may submit their bid in the office of Chairperson, Intellectual Property Management Cell, Room No. 117, Administration Block, Jawaharlal Nehru University, New Delhi-110067, so as to reach this office on or before 31st October 2014. For any further clarification and seeking appointment the interested parties can contact: Professor Ashwani Pareek, School of Life Sciences, Jawaharlal Nehru University, New Delhi-110067 by email: ashwanipareek@gmail.com or Phone 26704504.

 

Plant Biotechnology, Pharmaceutical and Seed Industries

4.

Stable integration of a xenobiotic receptor promoter-reporter DNA construct into human liver cell line for evaluating the drugs by high throughput screening

 

The Pregnane & Xenobiotic Receptor (PXR; NR1I2), a member of the nuclear receptor super-family, is a well-known xenobiotic sensing receptor. The highly promiscuous nature of PXR allows it to interact with a wide range of structurally diverse chemicals. Ligand-activated PXR up-regulates the expression of drug-metabolizing enzymes and drug transporters to protect the cell from chemical insults. However, the physiological importance of PXR extends beyond xenobiotic protection. Most importantly, the regulation of drug-metabolizing enzymes by PXR may result in clinical drug–drug interactions, in which one drug accelerates the metabolism of a second medication and may change or cause adverse results. This not only reduces the therapeutic efficacy of many drugs on combination therapy but may also cause life-threatening situations. Therefore, the complete evaluation and safety assessment of any drug (clinical or herbal) which is to be administered is indispensable.  Although there are various methods, which are available to assess the pharmacological properties by drug screening, but due to their high cost, lengthy experimental duration offers only limited use.In this context, a cell based screening approach for evaluating the therapeutic value and safety assessment of clinical or herbal drugs, xenobiotics and endobiotics are capable of being addressed at two main levels by engaging (i) PXR protein based or (ii) PXR-promoter based transcription assays:

 

Cell based screening protocol for 'Level 1' is already available (22, EPO- WO2004016759, USPTO- 20040077080) but cell based screening protocol for 'Level 2' is now possible here. The present claim relates to achievement of 'Level 2' screening for drugs, xenobiotics and endobiotics. This screening is achieved with the use of PXR-promoter-reporter construct that we have developed and stably integrated into a human liver cell line. Additional advantages of this stable PXR-promoter-reporter cell line would be in its ability to predict potential drug-drug interactions, to identify PXR regulatory proteins, and also to evaluate the modulatory effects of an experimental molecule on PXR promoter activity.

 

In conclusion, the present invention relates to a stably integrated PXR promoter-reporter construct-cell line comprising PXR promoter of -1096 to +43 region which is capable of assessing drug's capability to bind and induce PXR-promoter on its administration, and hence, is capable of indirectly influencing the protein level of the PXR-promoter on its administration so as to avoid failure of combination therapy. In one embodiment, it relates to a method of preparation of stably integrated PXR promoter-reporter construct-cell line. In another embodiment, it relates to a PXR promoter and to a PXR-promoter-reporter construct.

 

Interested parties who want to bid for the technology may submit their bid in the office of  Chairperson, Intellectual Property Management cell, Room No.117, Administration Block, Jawaharlal Nehru University, New Delhi-110067, so as to reach this office on or before 20th August, 2012. For any further clarification and seeking appointment the interested parties can contact: Dr. Rakesh K. Tyagi, Special Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi -110067 by e.mailrktyagi@yahoo.com

Include Pharmaceutical companies and industries industries involved in toxicological evaluation of xenobiotics (clinical drugs, herbal drugs pesticides etc) and endobiotic metabolites.

5.

HYBRID-TYPE HISTIDINE KINASE GENE ISOLATED FROM INDICA RICE IR64

 

The present invention provides a hybrid-type histidine kinase gene isolated from indica rice IR64, and being capable of osmosensing and inducible by multiple stresses, and hence, being capable of improving the multiple stress tolerance of the crop plants even in subsequent generations so as to make the plants capable of coping- up with the more than one environmental abiotic stress conditions, and therefore, increasing the economic value of the crop plants while maintaining the yield thereof. The present invention also provides a method of isolation of hybrid-type histidine kinase gene from indica rice IR64, and its functional characteristics and its sequence listing and cloning, at least, with yeast expression vector and the plant expression vector, and clones produced thereby, and method of improving multiple stress tolerance of crop plant and crop plants having improved multiple stress tolerance. Patent application (Indian as well as PCT) has been filed.

 

Interested parties who want to bid for the technology may submit their bid in the office of  Chairperson, Intellectual Property Management cell, Room No.117, Administration Block, Jawaharlal Nehru University, New Delhi-110067, so as to reach this office on or before 15th January 2011. For any further clarification and seeking appointment the interested parties can contact: Ashwani Pareek, School of Life Sciences Jawaharlal Nehru University, New Delhi -110067 by email: ashwanipareek@gmail.com 

All  Pharmaceutical Industries

6.

METHOD FOR ENHANCING REGENERATION FREQUENCY OF BRASSICA SPECIES

 

The present invention relates to a method for enhancing the regeneration frequency of varieties of Brassica sps., wherein the method is characterized by comprising treatment of hypocotyls explants segments of Brassica sps. with a medium comprising Benzyl Amino Purine and Napthalene Acetic Acid [B1N1 medium], wherein the treatment results in fast callus initiation, root hairs initiation, appearance of green spots in the callus so formed, and granulation of callus so formed, and appearance of anthocyanin pigmentation in few species of Brassica. Patent application (Indian as well as PCT) has been filed.

 

Interested parties who want to bid for the technology may submit their bid in the office of  Chairperson, Intellectual Property Management cell, Room No.117, Administration Block, Jawaharlal Nehru University, New Delhi-110067, so as to reach this office on or before 5th January 2011. For any further clarification and seeking appointment the interested parties can contact: Ashwani Pareek, School of Life Sciences Jawaharlal Nehru University, New Delhi -110067 by email: ashwanipareek@gmail.com

All  Pharmaceutical Industries

7.

CURCUMIN NANO FORM FOR MALARIA THERAPY

 

Curcumin, the yellow pigment present in the Indian spice turmeric, has great therapeutic potential. But it has not yet become possible to use it as a drug due to it’s poor bioavailability. We have developed the technology to prepare the nano form of pure curcumin which when administered orally to mice and rats shows about 10 times increased bioavailability in comparison to normal curcumin and cures Plasmodium yoelii infection in mice. The nano form of curcumin does not show any toxicity in mice and rats when fed for 21 days at 1gm/Kg body weight. Feeding 1 gm of curcumin in nano form to healthy human volunteers for 15 days did not show any adverse effect. It retains it’s bioactivity in the powder form for 1 year when kept at room temperature. Patent application (Indian as well as PCT) has been filed to protect our IPR. Interested parties who want to bid for the technology may submit their bid in the office of Chairperson, Intellectual Property Management Cell, Room no 117, Administration Block, JNU, NewDelhi-110067. Tel: 011-26704093, Fax: +91 1126742040 E-mail: ipmcell@mail.jnu.ac.in  by 5 pm of 30thJuly, 2010. For any further clarification and seeking appointment the interested parties can contact: Prof. Santosh K Kar, School of Biotechnology, Jawaharlal Nehru University, New Delhi by email: santoshkariis@rediffmail.com

 

All  Pharmaceutical Industries

8.

 

The technology for very long life incandescent Bulb and Fluorescent tube

has been developed for normal lighting purposes that can be further modified for several applications. The invention is of great commercial application and can be exploited very well in next 10-20 years. The Interested parties are hereby requested to submit a letter of intent to this effect and invited to discuss the invention, following signing a non-disclosure agreement. The license agreement will include, amongst others, provisions for upfront payments, royalty percentages and infringement issues. Intent for the said technology may be submitted in sealed covers to The Chairperson, Intellectual Property Management cell, Room No.117, Administration Block, Jawaharlal Nehru University, New Delhi-110067, so as to reach this office on or before close of work on Friday, June 30, 2009. Interested parties may also contact: Prof. Shatendra K Sharma, Director, University Science  Instrumentation Centre, Jawaharlal Nehru University, New Delhi 110067, India. Tel: (011)-26742604 (0), 9810721748(M) email: sksharma@mail.jnu.ac.in /shatendra@gmail.com

 

All manufacturers in lighting industry such as Philips, OSRAM, ECE, Bajaj, Surya, Sylvania Laxman etc.

9.

A novel process and apparatus for producing metal particles of various sizes (5-20 nm), by electro-explosion of wires, has been developed by Prof. Prasenjit Sen, School of Physical Sciences. The invention comprises detailed processes which cause a metal wire to explode into particles. Interested parties are hereby requested to submit a letter of intent to this effect and invited to discuss the invention, following signing a non-disclosure agreement. The license agreement will include, amongst others, provisions for upfront payments, royalty percentages and infringement issues. Intent for the said technology may be submitted in sealed covers to The Chairperson, Intellectual Property Management cell, Room No.117, Administration Block, Jawaharlal Nehru University, New Delhi-110067, so as to reach this office on or before close of work on Friday, May 15, 2009.Interested parties may also contactProf. Prasenjit Sen, School of Physical Sciences, Jawaharlal Nehru University, New Delhi 110067, India. Tel: (011)-26738773, (0)9899639944 ; email: psen0700@mail.jnu.ac.in

All manufacturing company which market the particle generator in India only.

10.

DNA vaccine based on a protective antigen of Rabies virus

 

The technology has been developed by Prof. Rakesh Bhatnagar of School of Biotechnology (SBT). Interested parties who want to bid for the said technology may submit their bids by 5.00 p.m. 11th November 2008 in the office of Chairperson, Intellectual Property Management cell, Room No.117 Administration Block, Jawaharlal Nehru University, New Delhi-110067.We have developed a DNA vaccine based on a protective antigen of Rabies virus. Here, the protective antigen was cloned in a DNA vaccine vector, wherein a signal sequence is used to direct the target antigen to a desired location, so as to generate maximum immune response. This vaccine has been tested in mice and dog models, wherein it generated high rabies virus neutralizing antibody titers, which were 64 and 16 times respectively; higher than the minimum adequate titer against rabies as recommended by WHO. Thus, this DNA vaccine is highly effective in mice and dogs. Further, this vaccine confers 100% protection, on intracerebral rabies virus challenge in mice. Patent regarding this invention has already been filed. (We have already filed an Indian patent as well as PCT to protect our IPR) Interested parties may also contact: Prof. Rakesh Bhatnagar F.N.A.Sc.Laboratory of Molecular Biology and Genetic Engineering, School of Biotechnology, Jawaharlal Nehru University, New Delhi 110067, India.Tel: (011)-26704079, 09891446032Fax: 26742040

 

All pharmaceutical Industries

11.

The Improved Design of Battery for Longer life

 

The technology has been developed by Prof. Shatendra Sharma of Advanced Instrumentation Facility (AIF). Interested parties who want to bid for the said technology may submit their bids by 5.00 p.m. 31st December 2008 in the office of Chairperson, Intellectual Property Management cell, Room No.117 Administration Block, Jawaharlal Nehru University, New Delhi-110067. Interested parties may also contact the inventor: Prof. Shatendra Sharma Ph.D. F.I.E., F.I.E.T.E., Director, University Science Instrumentation Centre, Jawaharlal Nehru University, New Delhi 110067, India.Tel: (011)-26742604, 09810721748, Fax: 26742604

 

All leading Battery Manufacturers like Exide, Panasonic, Okaya, Amco, Sanyo, Hitachi, Luminous  and others

12.

An improved Design of  Beverage Packing Can

The technology has been developed by Prof. Shatendra Sharma of Advanced Instrumentation Facility (AIF). Interested parties who want to bid for the said technology may submit their bids by 5.00 p.m. 31st December 2008 in the office of Chairperson, Intellectual Property Management cell, Room No.117 Administration Block, Jawaharlal Nehru University, New Delhi-110067. Interested parties may also contact the inventor: Prof. Shatendra Sharma Ph.D. F.I.E., F.I.E.T.E., Director, University Science Instrumentation Centre, Jawaharlal Nehru University, New Delhi 110067, India.Tel: (011)-26742604, 09810721748, Fax: 26742604

 

All large scale Manufacturers like Coke, Pepsi, Essel packagings,  Fruit juice, milk, Wine, Beer and  all types of beverage manufacturers.

13.

An improved design of  Ignition Spark Plug for Internal Combustion Engines

 

The technology has been developed by Prof. Shatendra Sharma of Advanced Instrumentation Facility (AIF). Interested parties who want to bid for the said technology may submit their bids by 5.00 p.m. 31st December 2008 in the office of Chairperson, Intellectual Property Management cell, Room No.117 Administration Block, Jawaharlal Nehru University, New Delhi-110067. Interested parties may also contact the inventor: Prof. Shatendra Sharma Ph.D. F.I.E., F.I.E.T.E., Director, University Science Instrumentation Centre, Jawaharlal Nehru University, New Delhi 110067, India.Tel: (011)-26742604, 09810721748, Fax: 26742604

 

All OEM Manufacturers like  Mico, Lucas etc. and other automobile component manuafcturers